Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Mario Gabelli, GAMCO, & Tredegar Corporation (TG)’s Poison Pill

Mario Gabelli‘s fund GAMCO Investors, in a newly amended filing with the Securities and Exchange Commission has provided an update regarding its negotiations with the management of Tredegar Corporation (NYSE:TG). The fund sent a letter to General Counsel and Corporate Secretary of the company, Mr. A. Brent King, in which it proposes that the shareholders of the company should vote on the Shareholders Rights plan installed by the Board earlier.

“GAMCO is proposing a resolution that urges the shareholders to vote to request that the Board of Directors redeem the rights issued pursuant to the Rights Agreement, dated as of June 30, 1999, and thereafter amended and restated on June 30, 2009 and November 18, 2013,” the letter stated.

Mario Gabelli

The latest amendment to the Shareholders Rights plan, also known as the Poison Pill, among other things involves raising the threshold for launching the plan to 20% from previously stated 15%. Also, Tredegar Corporation (NYSE:TG)’ shareholders that own at least 10% of the common stock, received the right to request a special meeting to vote to  cancel the Revised Rights Agreement.

Mario Gabelli via GAMCO, Gabelli Funds, and Teton Advisors holds a total of 14.12% of Tredegar’s common stock. The position involves 4.6 million shares. Out of the total position, GAMCO owns over 3.8 million shares, equal to 11.84% of the common stock. Earlier in October, GAMCO sent another letter to the company, mentioning that the fund would consider proposing a vote regarding the poison pill policy. The fund also stated that they “remain committed to shareholder value creation”

Among other shareholders of Tredegar, Cliff Asness’s Aqr Capital Management holds a stake which contains almost 94,200 shares, with a reported value of over $2.4 million.  Jim Simons’s Renaissance Technologies reported, in its latest 13F, closing the position in Tredegar, previously owning 22,300 shares.

Disclosure: none

Recommended Reading:

Gabe Hoffman’s Accipiter Capital Decreases Holding of Triple-S Management Corp. (GTS) Stock

Jeremy Green, Redmile Group Boost Position in Amicus Therapeutics, Inc. (FOLD)

Tontine Asset Management Sells Patrick Industries (PATK) and Westmoreland Coal Company (WLB) Shares

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!